Condition: Solid Tumor · Sarcoma · Leiomyosarcoma · Sponsor: STORM Therapeutics LTD
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in advanced unresectable or metastatic tumors. The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).
This description comes directly from the study's public registry record.
Sandra Tong, MD · 650-399-6357 · sandy.tong@stormtherapeutics.com
Melinda Snyder · 617-233-4057 · melinda.snyder@stormtherapeutics.com
Always discuss trial participation with your own doctor first.
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Northwell Health Cancer Institute | Lake Success, New York, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Not Yet Recruiting |
| NEXT Houston | Houston, Texas, United States | Recruiting |
| NEXT Dallas | Irving, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| The START Center | San Antonio, Texas, United States | Recruiting |
| NEXT Oncology | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06975293